It can lower serum levels of VEGF, OPN, and Egfl7 in patients and prevent liver damage, which is one of the key reasons for the large reduction in tumor marker levels in HCC patients treated with combination therapy and the further improvement of the curative effect. This evidence concerns the gene SPP1 and hepatocellular carcinoma.